IS8478A - Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess - Google Patents

Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess

Info

Publication number
IS8478A
IS8478A IS8478A IS8478A IS8478A IS 8478 A IS8478 A IS 8478A IS 8478 A IS8478 A IS 8478A IS 8478 A IS8478 A IS 8478A IS 8478 A IS8478 A IS 8478A
Authority
IS
Iceland
Prior art keywords
rosuvatatin
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
Prior art date
Application number
IS8478A
Other languages
English (en)
Inventor
Okada Tetsuo
Horbury John
Dermot Patrick Laffan David
Original Assignee
Astrazeneca Uk Limtied
Shionogi & Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8478(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Limtied, Shionogi & Company Limited filed Critical Astrazeneca Uk Limtied
Publication of IS8478A publication Critical patent/IS8478A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8478A 2003-10-24 2006-05-22 Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess IS8478A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324791.3A GB0324791D0 (en) 2003-10-24 2003-10-24 Chemical process
PCT/GB2004/004481 WO2005042522A1 (en) 2003-10-24 2004-10-22 Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof

Publications (1)

Publication Number Publication Date
IS8478A true IS8478A (is) 2006-05-22

Family

ID=29595716

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8478A IS8478A (is) 2003-10-24 2006-05-22 Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess

Country Status (28)

Country Link
US (2) US20070255060A1 (is)
EP (2) EP2272842A1 (is)
JP (3) JP2007509119A (is)
KR (1) KR20060132829A (is)
CN (2) CN1898233B (is)
AR (1) AR046191A1 (is)
AU (1) AU2004285750B2 (is)
BR (1) BRPI0415681A (is)
CA (1) CA2543358A1 (is)
CY (1) CY1114145T1 (is)
DK (1) DK1682536T3 (is)
ES (1) ES2404693T3 (is)
GB (1) GB0324791D0 (is)
IL (1) IL175086A0 (is)
IS (1) IS8478A (is)
MY (1) MY146002A (is)
NO (1) NO20062263L (is)
NZ (1) NZ547094A (is)
PL (1) PL1682536T3 (is)
PT (1) PT1682536E (is)
RU (1) RU2372349C2 (is)
SA (1) SA04250425B1 (is)
SI (1) SI1682536T1 (is)
TW (1) TWI344957B (is)
UA (1) UA83076C2 (is)
UY (1) UY28577A1 (is)
WO (1) WO2005042522A1 (is)
ZA (1) ZA200603173B (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
MXPA04000322A (es) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
KR101060215B1 (ko) 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
CA2612587C (en) * 2005-06-24 2013-02-19 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP2024341B1 (en) 2006-05-03 2015-12-02 MSN Laboratories Private Limited Novel process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008096257A1 (en) * 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
JP2010501643A (ja) * 2007-07-12 2010-01-21 テバ ファーマシューティカル インダストリーズ リミティド 薄膜蒸発及び化学的手法によるロスバスタチン中間体の精製
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US8793497B2 (en) * 2008-05-09 2014-07-29 Qualcomm Incorporated Puzzle-based authentication between a token and verifiers
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2389365A1 (en) 2009-01-15 2011-11-30 Egis Gyógyszergyár Nyilvánosan Müködö Process for the preparation of rosuvastatin salts
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
US8846915B2 (en) 2009-08-17 2014-09-30 Aurobindo Pharma Ltd. Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
EP2336116A1 (en) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN102219749B (zh) * 2010-04-14 2013-07-17 上海京新生物医药有限公司 一种制备瑞苏伐他汀钙的方法
CA2796964A1 (en) 2010-04-23 2011-10-27 Ranbaxy Laboratories Limited Intermediates for the preparation of hmg-coa reductase inhibitors
JP5822169B2 (ja) * 2010-07-01 2015-11-24 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN103313983B (zh) * 2011-01-18 2016-06-29 中化帝斯曼制药有限公司荷兰公司 在碱存在下制备他汀类化合物的方法
CN103848790B (zh) * 2012-12-05 2016-08-03 安徽省庆云医药化工有限公司 瑞舒伐他汀酯的晶型及其制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
EP3103878A4 (en) 2014-02-06 2017-08-16 API Corporation Rosuvastatin calcium and process for producing intermediate thereof
CN105153040B (zh) * 2015-10-15 2018-04-13 江苏师范大学 瑞舒伐他汀钙新晶型及其制备方法
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
AU3214689A (en) 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ES2106926T3 (es) 1992-07-02 1997-11-16 Hoechst Ag Procedimiento para la preparacion del ester terc-butilico del acido (3r,5s)6-hidroxi-3,5-o-isopropiliden-3,5-dihidroxi-hexanoico.
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
WO1997049681A1 (en) 1996-06-24 1997-12-31 Astra Aktiebolag (Publ) Polymorphic compounds
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
CN1122029C (zh) 1998-12-10 2003-09-24 钟渊化学工业株式会社 制备辛伐他汀的方法
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
ES2234699T3 (es) 1999-11-17 2005-07-01 Teva Pharmaceutical Industries Ltd. Forma polimorfica de atorvastatina calcio.
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1468098A (zh) 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
PL362981A1 (en) 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (is) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CZ20033329A3 (cs) 2001-06-06 2004-11-10 Bristol-Myers Squibb Company Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
MXPA04000322A (es) * 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
JP2005503393A (ja) 2001-08-22 2005-02-03 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド インドール誘導体の製造方法
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EA200401533A1 (ru) 2002-05-21 2005-06-30 Ранбакси Лабораторис Лимитед Способ получения росувастатина
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DK1578733T3 (da) 2002-12-10 2011-06-14 Ranbaxy Lab Ltd Fremgangsmåde til fremstilling af rosuvastatin
KR101060215B1 (ko) * 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
AU2004228607B2 (en) 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003247327A1 (en) 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1678148A1 (en) 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CN1894221B (zh) 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
CA2550742A1 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
EP1797046A2 (en) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
WO2006079611A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
JP4614238B2 (ja) * 2006-07-14 2011-01-19 ルネサスエレクトロニクス株式会社 Ｒｆ電力増幅装置
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
UY28577A1 (es) 2005-06-30
SA04250425B1 (ar) 2009-08-11
MY146002A (en) 2012-06-15
ZA200603173B (en) 2007-07-25
NO20062263L (no) 2006-05-19
GB0324791D0 (en) 2003-11-26
CY1114145T1 (el) 2016-07-27
CA2543358A1 (en) 2005-05-12
DK1682536T3 (da) 2013-05-06
HK1092462A1 (en) 2007-02-09
WO2005042522A1 (en) 2005-05-12
AU2004285750B2 (en) 2008-03-13
AR046191A1 (es) 2005-11-30
EP1682536A1 (en) 2006-07-26
JP2008024712A (ja) 2008-02-07
CN1898233B (zh) 2012-06-13
JP2008044948A (ja) 2008-02-28
JP2007509119A (ja) 2007-04-12
AU2004285750A1 (en) 2005-05-12
US9371291B2 (en) 2016-06-21
EP1682536B1 (en) 2013-02-27
SI1682536T1 (sl) 2013-07-31
PL1682536T3 (pl) 2013-08-30
TW200523256A (en) 2005-07-16
IL175086A0 (en) 2006-08-20
CN101654453A (zh) 2010-02-24
PT1682536E (pt) 2013-05-06
TWI344957B (en) 2011-07-11
RU2372349C2 (ru) 2009-11-10
CN1898233A (zh) 2007-01-17
BRPI0415681A (pt) 2006-12-19
ES2404693T3 (es) 2013-05-28
UA83076C2 (en) 2008-06-10
RU2006117337A (ru) 2007-12-10
CN101654453B (zh) 2012-07-04
NZ547094A (en) 2009-05-31
EP2272842A1 (en) 2011-01-12
KR20060132829A (ko) 2006-12-22
US20110301348A1 (en) 2011-12-08
US20070255060A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS8385A (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó] pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
EE05288B1 (et) 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
HUP0104828A3 (en) Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation
MY135301A (en) Chemical process
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
NO20061324L (no) Polymorfe former av en kjent antihyperlinemisk forbindelse
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
TH73095A (th) กระบวนการทางเคมีและอินเทอร์มีเดียต